Experienced in Malignant Peripheral Nerve Sheath Tumor

Dr. Ashiq M. Masood

Hematology Oncology | Hematology | Oncology
University Medical Diagnostic Associates Inc
535 Barnhill Dr, 
Indianapolis, IN 
Accepting New Patients
Experienced in Malignant Peripheral Nerve Sheath Tumor
University Medical Diagnostic Associates Inc
535 Barnhill Dr, 
Indianapolis, IN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ashiq Masood is a Hematologist Oncology specialist and a Hematologist in Indianapolis, Indiana. Dr. Masood is rated as an Experienced provider by MediFind in the treatment of Malignant Peripheral Nerve Sheath Tumor. His top areas of expertise are Pancreatic Cancer, Colorectal Cancer, Familial Pancreatic Cancer, Neuroendocrine Tumor, and Tissue Biopsy. Dr. Masood is currently accepting new patients.

His clinical research consists of co-authoring 40 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in IN
Hospital Affiliations
Indiana University Health
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

UNIVERSITY MEDICAL DIAGNOSTIC ASSOCIATES INC
535 Barnhill Dr, Indianapolis, IN 46202
Other Locations
IU HEALTH MEDICAL GROUP LLC
1701 N Senate Blvd, Indianapolis, IN 46202

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma
A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma
Enrollment Status: Completed
Publish Date: October 08, 2025
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Capecitabine, Chemotherapy, Erlotinib hydrochloride, Fluorouracil, Gemcitabine hydrochloride
Study Phase: Phase 3
An Open-label Window of Opportunity Trial to Evaluate the Activity of Durvalumab (MEDI4736) and Tremelimumab With Platinum-based Chemotherapy (Gemcitabine and Cisplatin) in Intrahepatic Cholangiocarcinoma (ICC)
An Open-label Window of Opportunity Trial to Evaluate the Activity of Durvalumab (MEDI4736) and Tremelimumab With Platinum-based Chemotherapy (Gemcitabine and Cisplatin) in Intrahepatic Cholangiocarcinoma (ICC)
Enrollment Status: Terminated
Publish Date: November 05, 2024
Intervention Type: Drug
Study Drug: Chemotherapy+Immunotherapy
Study Phase: Phase 1/Phase 2
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: October 31, 2024
Intervention Type: Drug, Device
Study Drugs: Gemcitabine, Nab-paclitaxel
Study Phase: Phase 3
A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies
A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies
Enrollment Status: Terminated
Publish Date: May 01, 2023
Intervention Type: Drug
Study Drugs: SEA-CD40, Pembrolizumab, Gemcitabine, Nab-Paclitaxel
Study Phase: Phase 1
DRAGON 1- Training, Accreditation, Implementation and Safety Evaluation of Portal and Hepatic Vein Embolization to Accelerate Future Liver Remnant (FLR) Hypertrophy
DRAGON 1- Training, Accreditation, Implementation and Safety Evaluation of Portal and Hepatic Vein Embolization to Accelerate Future Liver Remnant (FLR) Hypertrophy
Enrollment Status: Unknown
Publish Date: February 03, 2023
Intervention Type: Procedure
Study Phase: Not Applicable
Phase Ib Study of BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Phase Ib Study of BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Enrollment Status: Terminated
Publish Date: April 21, 2021
Intervention Type: Drug, Procedure
Study Phase: Phase 1
Genomic Landscape of EGFR Mutant NSCLC Prior to Erlotinib and at the Time of Disease Progression Following Erlotinib
Genomic Landscape of EGFR Mutant NSCLC Prior to Erlotinib and at the Time of Disease Progression Following Erlotinib
Enrollment Status: Terminated
Publish Date: July 18, 2019
A Phase II Study of MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
A Phase II Study of MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
Enrollment Status: Terminated
Publish Date: November 06, 2018
Intervention Type: Drug
Study Phase: Phase 2
A Phase I/II Study of Pacritinib in Patients With EGFR Mutant NSCLC After EGFR TKI
A Phase I/II Study of Pacritinib in Patients With EGFR Mutant NSCLC After EGFR TKI
Enrollment Status: Terminated
Publish Date: February 27, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 8 Less Clinical Trials

40 Total Publications

Primary tumor microbiomes predict distant metastasis of colorectal cancer.
Primary tumor microbiomes predict distant metastasis of colorectal cancer.
Journal: bioRxiv : the preprint server for biology
Published: July 15, 2025
Similar Doctors
Advanced in Malignant Peripheral Nerve Sheath Tumor
Dr. Samantha Armstrong
Hematology Oncology | Hematology | Oncology
Advanced in Malignant Peripheral Nerve Sheath Tumor
Dr. Samantha Armstrong
Hematology Oncology | Hematology | Oncology

Iu Health Medical Group LLC

1701 N Senate Blvd, 
Indianapolis, IN 
 (1.3 miles away)
888-484-3258
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Samantha Armstrong is a Hematologist Oncology specialist and a Hematologist in Indianapolis, Indiana. Dr. Armstrong is rated as a Distinguished provider by MediFind in the treatment of Malignant Peripheral Nerve Sheath Tumor. Her top areas of expertise are Undifferentiated Pleomorphic Sarcoma, Liposarcoma, Rhabdomyosarcoma Embryonal, and Ganglioneuroblastoma.

Experienced in Malignant Peripheral Nerve Sheath Tumor
Dr. Anna Roshal
Hematology Oncology | Oncology | Hematology
Experienced in Malignant Peripheral Nerve Sheath Tumor
Dr. Anna Roshal
Hematology Oncology | Oncology | Hematology

University Medical Diagnostic Associates Inc

550 N University Blvd, 
Indianapolis, IN 
 (0.1 miles away)
217-274-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Anna Roshal is a Hematologist Oncology specialist and an Oncologist in Indianapolis, Indiana. Dr. Roshal is rated as a Distinguished provider by MediFind in the treatment of Malignant Peripheral Nerve Sheath Tumor. Her top areas of expertise are Gastroesophageal Junction Cancer, Familial Colorectal Cancer, Paget Disease of the Breast, and Inflammatory Breast Cancer. Dr. Roshal is currently accepting new patients.

Experienced in Malignant Peripheral Nerve Sheath Tumor
Dr. Gregory A. Durm
Hematology Oncology | Oncology | Hematology
Experienced in Malignant Peripheral Nerve Sheath Tumor
Dr. Gregory A. Durm
Hematology Oncology | Oncology | Hematology

Iu Health Medical Group LLC

1701 N Senate Ave, 
Indianapolis, IN 
 (1.4 miles away)
317-962-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Gregory Durm is a Hematologist Oncology specialist and an Oncologist in Indianapolis, Indiana. Dr. Durm is rated as a Distinguished provider by MediFind in the treatment of Malignant Peripheral Nerve Sheath Tumor. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Small Cell Lung Cancer (SCLC), and Lung Adenocarcinoma. Dr. Durm is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Masood's expertise for a condition
ConditionClose
    View All 12 Advanced Conditions
    View All 68 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile